Navigation Links
Pharmasset Announces $45.5 Million Registered Direct Offering of Common Stock
Date:1/30/2009

at http://www.sec.gov or by calling Leerink Swann, toll free, at 1-800-808-7525, Ext. 4556.

About Pharmasset

Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).

Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding our business that are not historical facts are "forward-looking statements" that involve risks and uncertainties, including without limitation, the risk that this offering will not close, the risk that adverse events could cause the cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that the results of previously conducted studies involving our product candidates will not be repeated or observed in ongoing or future studies involving our product candidates, the risk that our collaboration with Roche will not continue or will not be successful and the risk that any one or more of our product candidates will not be successfully developed and commercialized. For a discussion of these risks and uncertainties, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section of our Annual Report on Form 10-K for the fiscal year ended September 30, 2008 filed with the Securities and Exchange Commission entitled "Risk Factors" and discussions of potential risks and uncertainties in our subsequent filings with the Securities and Exchange Commission. Pharmasset undertakes no obligation to publicly update forward-looking statem
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Pharmasset and Roche to Present R7128 Data at the 14th International Symposium on Hepatitis C Virus and Related Viruses
2. Pharmasset to Present at the UBS Global Life Sciences Conference on Monday, September 24th
3. Pharmasset Accesses up to $30 Million of Working Capital
4. Pharmasset to Present at Three Investor Conferences in November 2007
5. Pharmasset Appoints Michael Rogers as Chief Development Officer
6. Pharmasset Reports Fiscal Year End 2007 Financial Results
7. Pharmasset to Present at the BIO CEO & Investor Conference 2008 on Monday, February 11th
8. Pharmasset to Present at Susquehannas Second Annual SIGnificant Investment Options in Healthcare Conference on Wednesday, March 5th
9. Pharmasset to Present at Cowen & Companys Health Care Conference on Tuesday, March 18th
10. Pharmasset Appoints Herbert J. Conrad as a Director
11. Pharmasset Receives $10 Million of Working Capital
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... (PRWEB) December 23, 2014 “Preparative ... Gas, HPLC, Flash), Consumables (Columns, Solvents, Buffers, Valves, ... Food & Agriculture) - Forecasts to 2019” provides ... challenges, opportunities, current market trends, and strategies impacting ...
(Date:12/24/2014)... Earlier this year in a June 24 international conference ... Cell Technology Center, LLC ( ASCTC ) focused attention on ... tissue stem cells. His title “Asymmetric Self-Renewal by Distributed ... embodied the essence of his message to congress participants. ...
(Date:12/24/2014)... On Friday, December 19, 2014, President Obama signed ... Appropriations Act of 2015, which for the first time, ... the Congressionally Directed Medical Research Programs (CDMRP) administered by ... working in conjunction with its allies on Capitol Hill, ...
(Date:12/24/2014)... Dallas, Texas (PRWEB) December 23, 2014 ... mercaptan such as its definition, classification, application and ... manufacturing process, and product cost structure. Production is ... also covers upstream raw materials, equipment, downstream client ...
Breaking Biology Technology:Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2
... of the universities in the resund Region University ... together with MC2 at Chalmers University of Technology ... build up a network for co-operation within nanotechnology. , ... , Used efficiently, knowledge on nanotechnology will ...
... Required for Integra Merger, IRVINE, California, October 26 ... company, today announced that,it has adjourned its special meeting ... the acquisition of IsoTis by Integra,LifeSciences Holdings Corporation (NASDAQ: ... of merger dated as of August 6, 2007. ...
... Services,Inc. (NYSE: AHS ), the nation,s largest ... on Thursday, November 1, 2007 at 3.30 p.m.,Pacific ... place at the San,Diego Marriott Del Mar Hotel ... Susan R. Nowakowski, President and Chief Executive ...
Cached Biology Technology:IsoTis Adjourns Special Meeting to October 29, 2007 2IsoTis Adjourns Special Meeting to October 29, 2007 3IsoTis Adjourns Special Meeting to October 29, 2007 4AMN Healthcare Services to Present at the BIOCOM Investor Conference 2007 2
(Date:12/19/2014)... , Dec. 18, 2014   LaunchKey , the first ... post-password and Internet of Things era, today announced the ... venture round was led by Metamorphic Ventures with participation ... Partners, VegasTechFund, and others.  LaunchKey has raised $4 million ...
(Date:12/17/2014)... Dec. 15, 2014 The Defense Logistics Agency is ... and prevent counterfeit microcircuits from entering into its supply ... in-house microcircuit anti-counterfeit initiative dubbed DNA marking. The capability ... their reliability throughout the supply chain. The new quality ...
(Date:12/17/2014)... 2014 Valencell, a leader in performance biometric data ... industry leaders such as Intel, Jabra, Atlas, and Scosche ... products. These products will be showcased at CES 2015, ... . "Our partners choose PerformTek ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2
... and skeletal deformities in people has been shown to ... adult mice, according to a recent study led by ... in early bone development, controls bone mineral density in ... Mutations in matrilin-3 have previously been linked to certain ...
... of Minnesota researchers have found a group of cells ... to turn on T-cells, cells that help fight infection. ... 2006 issue of the journal Immunity, released today. , ... response will help in studying and developing treatments for ...
... a specific cell protein can trigger the spread of cancer. ... of Edinburgh Cancer Research Centre could pave the way for ... normal cell cancerous. , The protein, MDM2, normally functions ... called p53. In some of the body's cells, the biochemical ...
Cached Biology News:Matrilin-3 gene discovered to prevent onset of osteoarthritis 2Matrilin-3 gene discovered to prevent onset of osteoarthritis 3
DITHIOTHREITOL, 150UMOL, 1 EA. Dithiothreitol (DTT), 0.1 M Solution:, *0.1 M solution of DTT in high purity dH2O., *0.2 m filtered., *Storage: -20C. Category: SEQUENASE....
... Varian Cary 50 Microplate Reader ... cost per analysis by extending ... the award-winning Cary 50 instruments. ... to 384 samples in microlitre ...
... Polynucleotide Kinase for labeling of 5' ... acids. In the exchange reaction T4 ... group from DNA to ADP and ... to the free 5' hydroxyl group ...
ImageQuant 400, 1 EA. Category: ImageQuant CCD Imagers....
Biology Products: